Literature DB >> 11103938

Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling.

B Klockow1, M R Ahmadian, C Block, A Wittinghofer.   

Abstract

Mutations of Ras with three extra amino acids inserted into the phosphate-binding (P) loop have been investigated both in vitro and in vivo. Such mutants have originally been detected as oncogenes both in the ras and the TC21 genes. Biochemical experiments reveal the molecular basis of their oncogenic potential: the mutants show a strongly attenuated binding affinity for nucleotides, most notably for GDP, leading to a preference for GTP binding. Furthermore, both the intrinsic as well as the GAP-stimulated GTP hydrolysis are drastically diminished. The binding interaction with GAP is reduced, whereas binding to the Ras-binding domain of the downstream effector c-Raf1 is not altered appreciably. Microinjection into PC12 cells shows the mutants to be as potent to induce neurite outgrowth as conventional oncogenic Ras mutants. Unexpectedly, their ability to stimulate the MAP kinase pathway as measured by a reporter gene assay in RK13 cells is much higher than that of the normal oncogenic mutant G12V. This characteristic was attributed to an increased stimulation of c-Raf1 kinase activity by the insertional Ras mutants.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11103938     DOI: 10.1038/sj.onc.1203909

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

1.  Nucleotide pyrophosphatase employs a P-loop-like motif to enhance catalytic power and NDP/NTP discrimination.

Authors:  Ildikó Pécsi; Judit E Szabó; Scott D Adams; István Simon; James R Sellers; Beáta G Vértessy; Judit Tóth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-10       Impact factor: 11.205

2.  Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.

Authors:  Yline Capri; Elisabetta Flex; Oliver H F Krumbach; Giovanna Carpentieri; Serena Cecchetti; Christina Lißewski; Soheila Rezaei Adariani; Denny Schanze; Julia Brinkmann; Juliette Piard; Francesca Pantaleoni; Francesca R Lepri; Elaine Suk-Ying Goh; Karen Chong; Elliot Stieglitz; Julia Meyer; Alma Kuechler; Nuria C Bramswig; Stephanie Sacharow; Marion Strullu; Yoann Vial; Cédric Vignal; George Kensah; Goran Cuturilo; Neda S Kazemein Jasemi; Radovan Dvorsky; Kristin G Monaghan; Lisa M Vincent; Hélène Cavé; Alain Verloes; Mohammad R Ahmadian; Marco Tartaglia; Martin Zenker
Journal:  Am J Hum Genet       Date:  2019-05-23       Impact factor: 11.025

3.  KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.

Authors:  Katharina Balschun; Jochen Haag; Ann-Kathrin Wenke; Witigo von Schönfels; Nicolas T Schwarz; Christoph Röcken
Journal:  J Mol Diagn       Date:  2011-05-04       Impact factor: 5.568

4.  KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

Authors:  E Lopez-Crapez; L Mineur; H Emptas; P-J Lamy
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

5.  Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Authors:  Georgina L Ryland; Sally M Hunter; Maria A Doyle; Franco Caramia; Jason Li; Simone M Rowley; Michael Christie; Prue E Allan; Andrew N Stephens; David D L Bowtell; Ian G Campbell; Kylie L Gorringe
Journal:  Genome Med       Date:  2015-08-07       Impact factor: 11.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.